Archives of Disease in Childhood, Vol 75, 517-520, Copyright © 1996 by Archives of Disease in Childhood.

PAPERS

Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy

A Ornoy and E Cohen
Department of Anatomy and Cell Biology, Jerusalem Institute of Child Development, Hebrew University Hadassah Medical School and Ministry of Health, Israel.

AIM: The purpose of the study was to assess whether there was an increased rate of congenital anomalies or significant developmental delay in infants of women with epilepsy who had been treated with carbamazepine during pregnancy. METHODS: 47 children were studied, aged 6 months-6 years, who were born to 37 epileptic mothers on carbamazepine monotherapy (group A). All children had a complete physical and neurodevelopmental assessment by a developmental paediatrician, and 41 a complete psychological evaluation. They were compared with 47 children of similar socioeconomic status (group B). RESULTS: Six of the 47 children in group A had typical facial features of 'carbamazepine syndrome'. The average cognitive score of children in group A was significantly lower than in group B. This was mainly because all six children with carbamazepine syndrome had a development quotient or intelligence quotient below 90. There were no differences between the two groups in physical growth or in the rate of major anomalies. Two children in group A had cleft palate but in each case this was found in a parent as well. CONCLUSIONS: In utero exposure to carbamazepine may result in 'carbamazepine syndrome' characterised by facial dysmorphic features and mild mental retardation. Prevalence of carbamazepine syndrome does not seem to be related to the dose of carbamazepine or the presence of maternal convulsions. It may depend upon heredofamilial factors that have yet to be defined. One possible factor is decreased activity of the enzyme epoxide hydrolase with resulting increased concentrations of carbamazepine epoxide which may be teratogenic.

This article has been cited by other articles:

				U Kini, N Adab, J Vinten, A Fryer, J Clayton-Smith, and on behalf of the Liverpool and Manchester Neurodev Dysmorphic features: an important clue to the diagnosis and severity of fetal anticonvulsant syndromes Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2006; 91(2): F90 - F95. [Abstract] [Full Text] [PDF]

				J. Vinten, N. Adab, U. Kini, J. Gorry, J. Gregg, G. A. Baker, and for the Liverpool and Manchester Neurodevelopment Neuropsychological effects of exposure to anticonvulsant medication in utero Neurology, March 22, 2005; 64(6): 949 - 954. [Abstract] [Full Text] [PDF]

				Antiepileptics, pregnancy and the child DTB, February 1, 2005; 43(2): 13 - 16. [Abstract] [Full Text] [PDF]

				N Adab, U Kini, J Vinten, J Ayres, G Baker, J Clayton-Smith, H Coyle, A Fryer, J Gorry, J Gregg, et al. The longer term outcome of children born to mothers with epilepsy J. Neurol. Neurosurg. Psychiatry, November 1, 2004; 75(11): 1575 - 1583. [Abstract] [Full Text] [PDF]

				L. G. Costa, L. Steardo, and V. Cuomo Structural Effects and Neurofunctional Sequelae of Developmental Exposure to Psychotherapeutic Drugs: Experimental and Clinical Aspects Pharmacol. Rev., March 1, 2004; 56(1): 103 - 147. [Abstract] [Full Text] [PDF]

				E. Gaily, E. Kantola-Sorsa, V. Hiilesmaa, M. Isoaho, R. Matila, M. Kotila, T. Nylund, A. Bardy, E. Kaaja, and M. -L. Granstrom Normal intelligence in children with prenatal exposure to carbamazepine Neurology, January 13, 2004; 62(1): 28 - 32. [Abstract] [Full Text] [PDF]

				P. B. Pennell The importance of monotherapy in pregnancy Neurology, June 10, 2003; 60(90114): S31 - 38. [Abstract] [Full Text]

				J C S Dean, H Hailey, S J Moore, D J Lloyd, P D Turnpenny, and J Little Long term health and neurodevelopment in children exposed to antiepileptic drugs before birth J. Med. Genet., April 1, 2002; 39(4): 251 - 259. [Abstract] [Full Text] [PDF]

				O. Diav-Citrin, S. Shechtman, J. Arnon, and A. Ornoy Is carbamazepine teratogenic?: A prospective controlled study of 210 pregnancies Neurology, July 24, 2001; 57(2): 321 - 324. [Abstract] [Full Text] [PDF]

				L. B. Holmes, E. A. Harvey, B. A. Coull, K. B. Huntington, S. Khoshbin, A. M. Hayes, and L. M. Ryan The Teratogenicity of Anticonvulsant Drugs N. Engl. J. Med., April 12, 2001; 344(15): 1132 - 1138. [Abstract] [Full Text] [PDF]

				N Adab, A Jacoby, D Smith, and D Chadwick Additional educational needs in children born to mothers with epilepsy J. Neurol. Neurosurg. Psychiatry, January 1, 2001; 70(1): 15 - 21. [Abstract] [Full Text] [PDF]

				S J Moore, P Turnpenny, A Quinn, S Glover, D J Lloyd, T Montgomery, and J C S Dean A clinical study of 57 children with fetal anticonvulsant syndromes J. Med. Genet., July 1, 2000; 37(7): 489 - 497. [Abstract] [Full Text]

				E. M Rosser and L. C Wilson Drugs for epilepsy have teratogenic risks BMJ, May 8, 1999; 318(7193): 1289a - 1289. [Full Text]

				T. Parman, G. Chen, and P. G. Wells Free Radical Intermediates of Phenytoin and Related Teratogens. PROSTAGLANDIN H SYNTHASE-CATALYZED BIOACTIVATION, ELECTRON PARAMAGNETIC RESONANCE SPECTROMETRY, AND PHOTOCHEMICAL PRODUCT ANALYSIS J. Biol. Chem., September 25, 1998; 273(39): 25079 - 25088. [Abstract] [Full Text] [PDF]